Home Other Sections Medical News Transdermal Estradiol Progesterone Can Improve Cognitive Brain Function

Transdermal Estradiol Progesterone Can Improve Cognitive Brain Function

Affiliate Disclosure

In compliance with the FTC guidelines, please assume the following about all links, posts, photos and other material on this website: (...)


Transdermal Estradiol Progesterone Can Improve Cognitive Brain FunctionAnother investigation has shown that there are brain benefits of transdermal estradiol blended with an oral progesterone for postmenopausal women.

Hormones affect a great deal that goes ahead in a woman’s body, from reproductive functioning and sexual drive to weight gain and general psychological wellness.

Another investigation indicates how, in the correct dose and blend, hormones may enhance brain functioning in postmenopausal females as they age.



The results are published in Menopause, the journal of The North American Menopause Society (NAMS).

Estradiol Progesterone and Brain Function

It does not shock anyone that intellectual capacity decreases as we age.

We experience memory decline in a multitude of ways, such as forgetting a grocery list every now and then.

Mild cognitive impairment is characterized as that middle stage between aging and dementia.

Individuals with mild cognitive impairment have more danger of advancing to Alzheimer’s disease or other dementia, with about 20% of this population traversing from mild cognitive impairment to a more extreme degree every year.

To this point, no pharmacologic cure has been deemed to be effective in managing mild cognitive impairment.

Hormones and Mild Cognitive Impairment

The investigation is about the aftereffects of a Korean study that involves the consequence of hormone treatment on psychological capacity.

The study monitored postmenopausal women who were diagnosed with mild cognitive impairment and were taking donepezil over a 24-month period. The investigators confirmed that cognitive scan ratings for the women who received hormones enormously multiplied during that point.

Even though the group was small, the examination presents promising results, exhibiting that the blend of transdermalestradiol and an oral progesterone can back off cognitive decline. That is the first study to survey the aftereffects of hormone treatment on mild cognitive impairment.

This empowering, little pilot study recommends a conceivable advantage of hormone treatment when given to females who have mild cognitive impairment who are likewise taking donepezil, a cholinesterase inhibitor.

More cognition is one of the three key measures in those women who are using estradiol gel in addition to an oral micronized progesterone compared those taking placebo. More studies are needed to survey the results of hormone treatment use before the full start of Alzheimer disease.